FINWIRES · TerminalLIVE
FINWIRES

Immutep Says Median Overall Survival 30.9 Months for Non-Small Cell Lung Cancer Patients in Phase One Trial

By

Immutep (ASX:IMM) said the median overall patient survival was 30.9 months in patients in its INSIGHT-003 phase one trial, evaluating eftilagimod alfa, or efti, in combination with Merck's anti-PD-1 therapy Keytruda, or pembrolizumab, and chemotherapy as first-line therapy for advanced or metastatic non-small cell lung cancer in 51 evaluable non-squamous patients, according to a Monday Australian bourse filing.

Around 92% of patients enrolled in the trial had no or low programmed death-ligand 1 (PD-L1) expression, with a tumor proportion score under 50%. The median overall survival was 37.8 months in patients with a tumor proportion score of over 50%.

The results compare favorably with historical benchmarks, the filing said.

Preliminary immune monitoring data generated from its discontinued TACTI-004 phase three trial indicated that patients treated with efti showed a different immune activation profile compared with those observed in previous studies. The TACTI-004 analysis is ongoing, with additional results expected in the September quarter.

Related Articles

Asia

Claimants Withdraw Lawsuit Against PropNex's Arm

PropNex (SGX:OYY) said a lawsuit filed against the company's wholly-owned subsidiary, PropNex Realty, as a co-defendant, has been dropped, according to a Friday filing to the Singapore stock exchange.The claimants have discontinued and withdrawn the suit, the statement said.PropNex Realty was named as one of three co-defendants in a lawsuit filed in the High Court of Singapore in February. According to the lawsuit, claimants sought damages against PropNex Realty for alleged breach of duty of care and sought compensation of around SG$367,405 in damages.The withdrawal of the case is not expected to have any material impact on the financial position and performance of the group for the financial year ending Dec. 31.PropNex's shares were down nearly 1% in Monday's trade.

SGX:OYY
Asia

Dawning Information Industry Proposes Convertible Bond Issue for AI, Storage Push

Dawning Information Industry (SHA:603019) on Monday filed a prospectus for a convertible bond issue to unspecified investors.Proceeds are earmarked toward an artificial intelligence computing cluster system, a next-generation AI training-inference integrated machine and a domestic advanced storage system.Shares of the supercomputer manufacturer were down 1% in recent trade.

SHA:603019
Asia

Ampol Secures KKR as Cornerstone Investor in AU$400 Million Financing Transaction; Shares Up 3%

Ampol (ASX:ALD) secured a cornerstone investment from KKR in its AU$400 million financing transaction, according to a Monday statement from the investment firm.KKR is making this investment from its Asia Pacific Credit strategy and insurance platform, with support from Clifford Capital.Ampol will use the funds for refinancing initiatives and other general corporate purposes.Ampol's shares rose nearly 3% in recent trading on Monday.

ASX:ALD